Bio-Techne Conference Call Summary Company Overview - **Company**: Bio-Techne - **Industry**: Life Sciences and Diagnostic Tools - **Milestone**: Celebrating 50th anniversary in 2026, established in 1976 in Minneapolis [4][3] Core Business and Growth Verticals - Bio-Techne has developed a portfolio of approximately 6,000 complex molecules, focusing on proteins and antibodies, which provides a competitive advantage [5] - The company has branched into four growth verticals: 1. **Cell Therapy** 2. **Spatial Biology** 3. **Molecular Diagnostics** 4. **Core Reagents** [6] Recent Performance - **Fiscal 2Q Results**: Total organic growth was flat, with underlying organic growth at approximately 3% [7] - **Market Outlook**: Confidence in achieving mid-single digit organic growth by the end of fiscal 2026, supported by strong performance in large pharma, which accounts for 30% of revenues [9][10] Market Dynamics - **Large Pharma**: Experienced double-digit growth for five consecutive quarters, indicating strong momentum [9] - **Biotech Funding**: Funding has improved significantly, with a 90% increase over the last four months, expected to positively impact life science tools [10] - **Academic Market**: Represents 22% of revenue, with ongoing bipartisan support for education and research funding [11] Growth Pillars - **Cell and Gene Therapy**: Currently a $80 million run rate, with $60 million from GMP proteins and $20 million from small molecules and media [22][24] - **Wilson Wolf Acquisition**: Expected to enhance the cell and gene therapy portfolio, with a focus on the G-Rex bioreactor technology [32][35] - **Proteomic Analytical Tools**: The ProteinSimple franchise has shown high single-digit growth, with consumables growing in double digits [37] Margin Expansion - **Current Margins**: Bio-Techne has maintained margins above 30% despite market challenges [44] - **Future Outlook**: Potential for 100 basis points of margin expansion with a return to double-digit growth across end markets [45] M&A Strategy - M&A has been a critical part of Bio-Techne's growth strategy, with 18 acquisitions in the last 10 years [50] - The company is open to further acquisitions to enhance its portfolio, particularly in cell therapy workflows and proteomic analytics [51] Conclusion - Bio-Techne is well-positioned for future growth with a strong portfolio, improving market conditions, and strategic acquisitions planned to enhance its capabilities in the life sciences sector [50][51]

Core Viewpoint - He Yuan Bio (688238.SH) reported a mixed performance for the fiscal year 2025, with revenue growth but continued net losses [1] Financial Performance - The company achieved operating revenue of 267.66 million yuan, representing a year-on-year increase of 7.86% [1] - The net profit attributable to the parent company was a loss of 220.72 million yuan, which is a reduction in losses by 101.10 million yuan compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 232.02 million yuan, reflecting a decrease in losses by 103.89 million yuan year-on-year [1] Industry Context - The domestic biopharmaceutical sector is characterized by both opportunities and challenges, showcasing a complex landscape of diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] Operational Strategy - During the reporting period, the company emphasized strengthening customer resource reserves, enhancing brand influence, and promoting industry development [1] - The main performance goals included improving internal capabilities, upgrading operational management, and driving cost reduction and efficiency enhancement [1] - These efforts aim to gradually improve management quality and operational efficiency, laying a solid foundation for future business development [1]

Core Viewpoint - The company, Heyuan Bio, has announced a projected net loss for the fiscal year 2025, estimating a loss between 237 million yuan and 195 million yuan, although this represents a narrowing of losses compared to the previous year [1] Group 1: Business Impact - The domestic biopharmaceutical sector is experiencing a complex landscape of opportunities and challenges, characterized by diversified development and intense market competition [1] - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] - During the reporting period, all business segments of the company saw varying degrees of revenue growth, with a recovery in the cell and gene therapy industry expected in the second half of 2025 [1] Group 2: Operational Strategy - The company is prioritizing the enhancement of customer resource reserves, brand influence, and industry development, aiming to improve operational management capabilities and reduce costs [1] - Despite the planned advancement of the CDMO business, external factors such as insufficient downstream financing have impacted customer order prices, which remain at low levels compared to previous years [1] - The CDMO business has seen some improvement in gross margins, but high fixed operational costs related to depreciation, energy consumption, and daily maintenance have resulted in significant losses [1] Group 3: Impairment Provisions - Due to the ongoing losses in the cell and gene therapy CDMO business, the company has conducted preliminary impairment tests in accordance with accounting standards [1] - The company has made provisions for impairment related to inventory, long-term assets, and contract orders, which have negatively impacted the current net profit [1]

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry by leveraging strong technological capabilities and strategic focus, aiming to enhance its competitiveness and market penetration in the regenerative medicine sector [1][10]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1][2]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in the transition of China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company has made significant investments in R&D, with R&D expenses reaching 34.66 million yuan in the first three quarters of 2025, accounting for 19.22% of its revenue [3]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2][3]. - The integration of AI technology into drug development processes has been a focus, with the establishment of an intelligent R&D system that enhances efficiency [4]. Group 3: Market Position and Client Base - He Yuan Bio has built a robust client base, collaborating with over 14,700 research laboratories and managing more than 600 CDMO projects, including five Phase III clinical projects [5]. - The company emphasizes the importance of deep technical insights and precise control over process details as core values in its CRO and CDMO services [5]. Group 4: Future Development and Expansion - The company is expanding into the regenerative medicine sector by establishing a wholly-owned subsidiary, He Yuan He Mei, to address challenges in cell safety and traceability [8]. - The company’s production base in Lingang has commenced operations, featuring 11 GMP vector production lines and 18 GMP cell production lines, positioning it among the top in the international industry [6]. - He Yuan Bio aims to enhance its international presence by supporting domestic clients in obtaining overseas IND approvals and facilitating the licensing of proprietary technologies [9]. Group 5: Commitment to Health and Innovation - The company is committed to empowering cell and gene therapy to improve public health, focusing on innovation and collaboration to drive high-quality development in the CGT field [10].

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry, leveraging strong technological capabilities and strategic focus to navigate industry cycles and achieve significant growth [1][2]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in advancing China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company emphasizes continuous technological innovation, with a focus on core technical capabilities, GMP platform strength, and project management [2]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2]. - R&D expenses for the first three quarters of 2025 reached 34.66 million yuan, accounting for 19.22% of revenue, indicating a strong commitment to innovation [3]. Group 3: AI Integration - The company is actively exploring AI applications in drug development, creating an intelligent R&D system that integrates AI with biological technology [4]. - This dual-driven model of "algorithm innovation + application landing" aims to enhance R&D and production efficiency [4]. Group 4: Market Position and Client Base - He Yuan Bio has built a robust client base, with over 14,700 collaborative research laboratories and more than 600 CDMO projects, including 60 clinical trial approvals [5]. - The company provides a "one-stop" service from laboratory research to commercial production, focusing on technical insight and compliance [5]. Group 5: Future Development and Capacity Expansion - The company is positioned to capitalize on the transition of CGT drug commercialization from "technical breakthroughs" to "scale implementation," supported by technological advancements and policy backing [6]. - The company's Lingang industrial base has commenced full production, featuring 11 GMP vector production lines and 18 GMP cell production lines, placing it among the top in the international industry [6]. - Future capacity utilization at the Lingang base is expected to enhance market share and profitability, supporting growth in the cell and gene therapy sector [6]. Group 6: Expansion into Regenerative Medicine - He Yuan Bio is expanding into regenerative medicine by establishing a wholly-owned subsidiary, He Yuan He Mei, to address industry challenges related to cell safety and traceability [8]. - The company is developing processes for stem cells, immune cells, and exosomes, and is forming strategic partnerships to explore business development paths [8]. Group 7: Internationalization Efforts - The company is pursuing international expansion, aiming to position Chinese cell and gene therapy services on a global scale [8][9]. - He Yuan Bio has achieved a milestone with its Human Fibroblast Extracellular Vesicles being included in the global cosmetics ingredient directory, marking a significant step in its internationalization efforts [9]. Group 8: Commitment to Health and Innovation - He Yuan Bio is dedicated to empowering cell and gene therapy to enhance public health, driven by innovation and collaboration [10].

Core Insights - The company focuses on providing CRO and CDMO services for cell and gene therapy, as well as technical services in regenerative medicine and anti-aging fields [1][5][6] Financial Performance - For the period from January to September 2025, the company achieved a total revenue of 180 million yuan, a decrease of 1.91% year-on-year [1] - The CRO business generated revenue of 61.997 million yuan, reflecting a growth of 2.81% year-on-year, while the CDMO business revenue was 96.7021 million yuan, down 9.72% year-on-year [1] - Other main businesses, including research reagents and cell storage services, saw a revenue increase of 55.99%, totaling 21.3862 million yuan [1][2] Profitability - The company reported a net profit attributable to the parent company of -162 million yuan, which is a reduction in losses by 38.1258 million yuan compared to the same period last year [2] Business Development - The company has established over 14,700 collaborative research laboratories in the CRO sector and has completed over 600 CDMO projects, including five Phase III clinical projects [2] - The company has assisted clients in obtaining 60 clinical trial approvals, including 14 from the FDA [2] International Expansion - The company is expanding its CRO, CDMO, and regenerative medicine services overseas, utilizing online marketing and participation in influential academic conferences to enhance brand visibility [3] - A subsidiary has successfully registered Human Fibroblast Extracellular Vesicles with INCI, marking a significant milestone for global cosmetic market entry [3] Technological Advancements - The company is focusing on two core technology clusters and is exploring the application potential of emerging technologies in client projects [4] - AI technology is being integrated to enhance research efficiency and foster innovation through external collaborations [4] Market Trends - The company views the restructuring of domestic medical enterprises as a necessary step towards high-quality industry development, presenting new growth opportunities [5] - The company aims to leverage its extensive technical expertise and production capacity to meet the evolving market demands [5][6]

Core Viewpoint - The company is facing challenges in its cell and gene therapy CDMO business due to macroeconomic changes, industry conditions, and downstream demand, resulting in low order prices and negative gross margins, although there has been some improvement compared to the previous year [1][2]. Group 1: Company Overview - The company is focused on cell and gene therapy, which is a key development direction in the biopharmaceutical industry, supported by national and local policies [2]. - The company aims to enhance its competitiveness and market penetration by improving R&D efficiency, expanding into new business areas, and optimizing operations [2]. Group 2: Financial Data - The company reported a net loss of RMB 10,515.07 million for the first half of 2025, primarily due to low order prices and the early production stage of its projects [21]. - The company has fully utilized the raised funds for planned investments, with no reported issues in fund management or usage [10][20]. Group 3: Shareholder Information - The company has not disclosed any special arrangements regarding corporate governance or significant changes in major shareholders [3][4]. Group 4: Upcoming Events - The company will hold a performance briefing on August 27, 2025, to discuss its half-year results and address investor questions [5][8].

Core Viewpoint - The report highlights the ongoing challenges faced by the company in its cell and gene therapy CDMO business, including low order prices and high operational costs, while also emphasizing the potential for growth in the industry supported by favorable policies and technological advancements [1][6][11]. Financial Performance - The company reported a revenue of approximately 119.85 million yuan for the first half of 2025, representing a 6.01% increase compared to the same period last year [4]. - The total profit for the period was a loss of approximately 102.77 million yuan, an improvement from a loss of 113.36 million yuan in the previous year [4]. - The net profit attributable to shareholders was approximately -104.57 million yuan, showing a reduction in losses compared to -113.35 million yuan in the same period last year [4][5]. Industry Overview - The cell and gene therapy sector is identified as a key growth area in biomedicine, with significant advancements in technology and increasing clinical applications [7][11]. - The global pipeline for gene therapies has expanded, with over 4,469 gene therapy projects reported as of mid-2025, indicating a robust growth trajectory in the industry [10][11]. - The industry is characterized by a diverse landscape, with both large enterprises and numerous small to medium-sized companies, leading to a competitive environment [7][11]. Technological Advancements - Continuous innovation in gene editing and delivery technologies is crucial for the advancement of cell and gene therapies, with AI playing a significant role in enhancing research efficiency [8][9]. - Recent breakthroughs in stem cell therapy and regenerative medicine are paving the way for new clinical applications, demonstrating the potential for significant market growth [12][13]. Market Dynamics - The investment landscape for cell and gene therapy is showing signs of recovery in China, with a total financing amount of approximately 4.09 billion yuan in the first half of 2025, up from 2.57 billion yuan in the same period of 2024 [11][12]. - Despite the positive trends, the CDMO sector faces challenges due to the complexity and high costs associated with drug development and production, which may hinder rapid revenue growth [11][12]. Regulatory Environment - The government continues to support the cell and gene therapy industry through various policies aimed at promoting innovation and ensuring quality standards in drug development [14].

Core Viewpoint - The report highlights the ongoing challenges faced by He Yuan Biotechnology in its cell and gene therapy CDMO business, including low order prices and high operational costs, despite some improvements compared to the previous year [1][2]. Company Overview - He Yuan Biotechnology is listed on the Shanghai Stock Exchange with the stock code 688238, focusing on cell and gene therapy [2]. - As of the end of the reporting period, the total assets of the company were approximately 2.12 billion RMB, a decrease of 7.23% from the previous year [2]. Financial Performance - The company's revenue for the reporting period was approximately 119.85 million RMB, reflecting a year-on-year increase of 6.01% [3]. - The total profit for the period was a loss of approximately 102.77 million RMB, an improvement from a loss of 113.36 million RMB in the previous year [3]. - The net loss attributable to shareholders was approximately 104.57 million RMB, compared to a loss of 113.35 million RMB in the same period last year [3]. - The cash flow from operating activities showed a loss of approximately 88.50 million RMB, which is an improvement from a loss of 114.63 million RMB in the previous year [3]. - The weighted average return on net assets decreased by 0.69 percentage points to -6.35% [3]. Industry Context - The cell and gene therapy sector is identified as a key development area in the biopharmaceutical industry, supported by various national and local policies [2]. - The company aims to enhance its competitiveness and market penetration by improving R&D efficiency and expanding into new business areas [2].

Core Viewpoint - He Yuan Bio disclosed a research meeting with investors, highlighting its focus on domestic clients and the growth in the cell and gene therapy sector despite challenges in the broader healthcare financing landscape [1][2]. Company Overview - He Yuan Bio hosted an event titled "I am a Shareholder - Walk into the Listed Company" on July 18, 2025, attended by over 10 investors [2]. - The company is led by key personnel including Chairman and General Manager Pan Oudong, and other executives participated in the discussions [1]. Financial Performance - In 2024, the company achieved revenue of 248.15 million yuan, a year-on-year increase of 21.16%, with specific growth in CRO and CDMO segments [4]. - For Q1 2025, revenue was 52.85 million yuan, a decline of 11.29% compared to the previous year, primarily due to a drop in CDMO revenue [4]. Client Distribution - The company primarily serves domestic clients, with plans to expand its CRO services to pharmaceutical enterprises and enhance its international presence in the CDMO sector [3]. Data Security Measures - He Yuan Bio emphasizes data security, having achieved ISO27001 certification and implementing robust data management and protection systems [5]. CDMO Dependency - The company noted that the complexity of new drug development increases reliance on CDMO services, with over 65% of gene therapy companies outsourcing production [6]. Competitive Advantages - He Yuan Bio possesses a comprehensive CRO/CDMO technology platform, advanced GMP production facilities, and a strong project management capability, which collectively enhance its competitive edge in the cell and gene therapy market [6][7][8]. Cash Flow Situation - In 2024, the company reported a net cash flow of -218.09 million yuan, with ongoing challenges in cash flow due to extended payment cycles from clients [9]. - As of Q1 2025, the company continued to experience negative cash flow but anticipates improvement with the recovery of the investment environment [9]. Accounts Receivable and Bad Debt - As of December 31, 2024, the company had accounts receivable of 85 million yuan, with a bad debt provision of 6.96 million yuan, indicating a low risk of bad debts due to a strong client base [9]. Market Trends - In H1 2025, global healthcare financing decreased by 10%, while financing in China's cell and gene therapy sector increased to approximately 409 million USD, reflecting a recovery in this niche market [9].